NVO—Ozempic shows statsig weight loss in third/fourth phase-3 trials, completing phase-3 program: https://www.globenewswire.com/news-release/2020/06/12/2047467/0/en/Semaglutide-2-4-mg-shows-superior-weight-loss-versus-placebo-in-the-phase-3-trials-STEP-2-and-STEP-3-thereby-successfully-completing-the-programme.html